Phathom Pharmaceuticals (PHAT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Adjusted EPS
- —
- Estimate
- -$0.09
- Surprise
- +100.0%
- Revenue (period 2026-06-30)
- $74.3M
- Score at report (before → after)
- 6.7 → 6.7/10
Revenue source: xbrl.
How the report landed
TrendMatrix's engine moved from Buy (Wait) (6.7/10) to Hold at 6.7/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PHAT Sell at 6.5/10.
3 of the last 4 quarters beat the estimate; this quarter's +100.0% surprise compares with a +57.2% four-quarter average. Next scheduled report: 2026-10-29.
What argues against it
- Concentration risk — Product: VOQUEZNA
- Concentration risk — Counterparty: Takeda License
- DATA_ISSUE: analyst_target_implausible (raw $20.45 vs price $6.78 — ratio 3.0×). Rejected, falling back to technical TP.
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $6.78
- Price target
- $9.13
- Stop
- $6.32
- Upside to target
- +34.7%
Risk check: trading volume is running 1.5× its average — elevated turnover around the report window.
Model outputs from TrendMatrix’s engine as of 2026-10-07 — shown for context, not personalized investment advice.
PHAT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $548.5M
- P/E (fwd)
- 6.3
- 52-week range
- $6.52–$18.31
- Off 52-week high
- 63.0%
- RSI (14)
- 32
- Volume vs avg
- 1.51×
- Score today
- 6.5/10